Frank A Damelio bought stock once, on May 13, 2026

Frank A. D’Amelio is an experienced corporate executive and director who serves on the board of Zoetis Inc., where he has been a director since July 2012 and recently reported insider trading activity in his capacity as a board member.( A former Executive Vice President and Chief Financial Officer of Pfizer Inc., he played a central role in conceptualizing and executing the divestiture of Pfizer’s animal health business that created Zoetis as a standalone company, and has led acquisitions, partnerships, and divestitures valued at nearly $200 billion, including Pfizer’s acquisition of Wyeth.( He brings to Zoetis deep expertise in finance, global supply chains, information technology, and large-scale business transformations.(

D’Amelio’s career spans senior leadership roles at Pfizer, Alcatel‑Lucent, Lucent Technologies, AT&T, and Bell Labs, including positions such as Chief Operating Officer, Chief Financial Officer, Chief Administrative Officer, and head of Business Operations and Global Supply.( He currently serves on the boards of Humana Inc. (since 2003), Hewlett Packard Enterprise (since 2023), Viatris Inc. (since 2025), and has previously served on the board of Catalent Inc., as well as on private company boards such as Sail Biomedicines, Inc. and EntityRisk, Inc.( D’Amelio holds a bachelor’s degree in accounting from St. Peter’s College and an MBA in finance from St. John’s University.(

Written by Perplexity from public sources.